BioNTech SE
No SEC Form 4 filings for $BNTX in the last 30 days.
See all $BNTX insider activity →Arbutus and Genevant said they received about $178 million from Moderna under a March 2026 settlement. They also expanded US litigation against BioNTech and Pfizer to global Unified Patent Court claims over mRNA-LNP patents, seeking monetary relief and injunctions across multiple European countries. The UPC opposition hearing for one patent is set for Jan 2027.
BioNTech said its Supervisory Board selected Guido Oelkers, CEO of Stockholm-listed Sobi, as its next CEO. He will start no later than Feb. 1, 2027, ending a vacancy. BioNTech cited Oelkers’s role at Sobi, including revenue growth and deals such as Dova’s Doptelet acquisition. The company targets multiple oncology approvals by 2030 and is still searching for a new CMO.
BioNTech SE cut its 2026 revenue guidance to €1.6 billion to €1.9 billion, according to the company. It reported Q2 sales of €105.6 million and a net loss of €820.8 million, widening losses year over year. The article links the update to cash burn and execution risk in its oncology transformation and notes a pending CEO transition.
Over the past 7 days, alphai's AI scored 4 news stories mentioning BNTX (BioNTech SE). Coverage has skewed bearish: 0 bullish, 2 neutral, and 2 bearish.
Recent BNTX coverage spans earnings, financial news and market movers.
Expanded patent enforcement increases perceived IP risk and could pressure expectations around vaccine-related manufacturing/sales in affected jurisdictions.
CEO transition is a governance and execution catalyst, but the article provides no new financial guidance or trial readouts.
The guidance cut plus much wider losses directly weakens the near-term investment narrative and increases cash-burn and pipeline-execution risk.
CEO transition is a governance and execution signal for BioNTech’s shift from COVID vaccines to oncology pipeline commercialization.
Bios Life, a Boston startup linked to BioNTech alumni, emerged from stealth with a $25 million seed round and a multi-year data alliance with Tempus AI. It plans to use InstaDeep’s Nucleotide Transformer genomics model to continuously update AI cancer risk for about 40 million Americans, though it has not yet shown clinical proof for outcome prediction.
alphai scores every news story that mentions BNTX with an AI model for sentiment and relevance, and aggregates insider trades from BioNTech SE's SEC EDGAR Form 4 filings. Figures refresh continuously.
Arbutus and Genevant said they received about $178 million from Moderna under a March 2026 settlement. They also expanded US litigation against BioNTech and Pfizer to global Unified Patent Court claims over mRNA-LNP patents, seeking monetary relief and injunctions across multiple European countries. The UPC opposition hearing for one patent is set for Jan 2027.
7 min readBioNTech said its Supervisory Board selected Guido Oelkers, CEO of Stockholm-listed Sobi, as its next CEO. He will start no later than Feb. 1, 2027, ending a vacancy. BioNTech cited Oelkers’s role at Sobi, including revenue growth and deals such as Dova’s Doptelet acquisition. The company targets multiple oncology approvals by 2030 and is still searching for a new CMO.
6 min readBioNTech SE cut its 2026 revenue guidance to €1.6 billion to €1.9 billion, according to the company. It reported Q2 sales of €105.6 million and a net loss of €820.8 million, widening losses year over year. The article links the update to cash burn and execution risk in its oncology transformation and notes a pending CEO transition.
5 min readBioNTech (BNTX) named Guido Oelkers, CEO of Swedish rare-disease firm Sobi, as its next chief executive, effective Feb. 1, 2027, succeeding co-founder Ugur Sahin. The company said 2026 revenue guidance was lowered to $1.85B-$2.19B after Q2 revenue fell 60% Y/Y to $121.8M and net loss widened to over $946.3M.
4 min readBios Life, a Boston startup linked to BioNTech alumni, emerged from stealth with a $25 million seed round and a multi-year data alliance with Tempus AI. It plans to use InstaDeep’s Nucleotide Transformer genomics model to continuously update AI cancer risk for about 40 million Americans, though it has not yet shown clinical proof for outcome prediction.
7 min readBioNTech (BNTX) reported Q2 2026 revenue of EUR 106 million, down from EUR 261 million a year earlier, citing weaker U.S. COVID-19 vaccine demand and a prior-year Pfizer payment. It revised 2026 revenue guidance to EUR 1.6-1.9 billion. Adjusted R&D was EUR 477 million. Cash was EUR 16.6 billion at June 30, 2026, and it expects a EUR 613 million BMS collaboration payment in Q3.
8 min readPfizer (PFE) and BioNTech (BNTX) reported Q2 2026 results and updates after the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29. Pfizer posted Q2 revenue of $15.0B, Adjusted EPS $0.77, and raised full-year revenue guidance to $60.5–$62.5B. BioNTech’s Q2 revenue fell 59.5% to €105.6M and net loss widened to €820.8M, with guidance cut to €1.6–€1.9B.
7 min readBioNTech (BNTX) cut its 2026 revenue guidance to €1.6 billion to €1.9 billion from €2.0 billion to €2.3 billion after Q2 results showed higher losses and lower sales, according to the company. Shares were at $93.67, down 3.12% YTD and 16.11% over 1 year, per the article.
4 min readReuters reports BioNTech cut its 2026 revenue outlook to €1.6 billion to €1.9 billion from €2.0 billion to €2.3 billion, citing softer COVID-19 vaccine demand, use of stockpiles in Germany, and deferred milestone payments. Q2 revenue fell to €105.6 million and net loss rose to €820.8 million. Shares fell 5.5% after results.
3 min readBioNTech SE (BNTX) reported a Q2 net loss of 820.8 million euros, or 3.24 euros per share, versus 386.6 million euros a year earlier. Revenue fell to 105.6 million euros from 260.8 million euros, citing lower COVID-19 vaccine demand. The company cut its FY2026 revenue outlook to 1,600-1,900 million euros from 2,000-2,300 million euros.
3 min read
